Reldesemtiv治疗肌萎缩侧索硬化:COURAGE-ALS随机临床试验结果
COURAGE-ALS是一项双盲、安慰剂对照3期随机临床试验,在16个国家83个ALS中心纳入486例患者,评估口服reldesemtiv 300 mg每日两次 vs 安慰剂对24周ALSFRS-R总分变化的影响。因无效性提前终止,主要终点ALSFRS-R评分组间差异为-1.1(95%CI -2.17至-0.08;95%CI 0.77-1.10;
要点
- COURAGE-ALS因无效性提前终止,reldesemtiv未显示延缓ALS功能衰退的疗效。
核心结论
- 该随机临床试验未能证明reldesemtiv可延缓ALS的功能衰退。
研究设计与样本
- COURAGE-ALS为双盲、安慰剂对照3期随机临床试验,由16个国家83个ALS中心于2021年8月至2023年7月开展。
- 计划入组后随机分配至reldesemtiv组325例或安慰剂组161例,共486例;平均(SD)年龄59.4(10.9)岁,男性309例(63.6%);3例随机化患者未给药。
- 试验为混合去中心化设计,约一半访视远程进行,其余在门诊完成;前24周为安慰剂对照期,后24周所有参与者接受reldesemtiv,随后4周随访。
- 预设两次中期分析,第一次评估无效性,第二次评估无效性及可能样本量调整。
- 入组标准为符合修订El Escorial标准肯定、很可能或可能ALS伴下运动神经元体征,ALS症状≤24个月,ALSFRS-R总分≤44,用力肺活量≥预测值65%。
主要发现
- 随机化后24周第二次中期分析纳入256例参与者,数据监测委员会建议因无效性终止试验,申办方同意。
关键数值与推荐
- 干预方案:口服reldesemtiv 300 mg或安慰剂,每日两次。
- 主要终点:基线至第24周ALSFRS-R总分变化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment options for amyotrophic lateral sclerosis (ALS) remain suboptimal. Results from a phase 2 study of reldesemtiv in ALS suggested that it may slow disease progression. OBJECTIVE: To assess the effect of reldesemtiv vs placebo on functional outcomes in ALS. DESIGN, SETTING, AND PARTICIPANTS: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (COURAGE-ALS) was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted at 83 ALS centers in 16 countries from August 2021 to July 2023. The first 24-week period was placebo controlled vs reldesemtiv. All participants received reldesemtiv during the second 24-week period with a 4-week follow-up. Two interim analyses were planned, the first for futility and the second for futility and possible resizing. This was a hybrid decentralized trial with approximately half the trial visits performed remotely and the remaining visits in the clinic. Eligible participants met criteria for definite, probable, or possible ALS with lower motor neuron signs by modified El Escorial Criteria, ALS symptoms for 24 months or less, ALS Functional Rating Scale-Revised (ALSFRS-R) total score of 44 or less, and forced vital capacity of greater than or equal to 65% of predicted. INTERVENTIONS: Oral reldesemtiv, 300 mg, or placebo twice daily. MAIN OUTCOMES AND MEASURES: The primary end point was change in ALSFRS-R total score from baseline to week 24. RESULTS: Of the 696 participants screened, 207 were screen failures. A total of 486 participants (mean [SD] age, 59.4 [10.9] years; 309 male [63.6%]) were randomized to reldesemtiv (n = 325) or placebo (n = 161); 3 randomized patients were not dosed. The second interim analysis at 24 weeks after randomization included 256 participants. The data monitoring committee recommended that the trial should end due to futility, and the sponsor agreed. The mean (SE) group difference in the ALSFRS-R score from baseline to week 24 was -1.1 (0.53; 95% CI, -2.17 to -0.08; P = .04, favoring placebo). Given excess missing data from early termination, the combined assessment assumed greater importance; it, too, failed to show a benefit from treatment with reldesemtiv (win probability was 0.44 for reldesemtiv and 0.49 for placebo, with a win ratio of 0.91; 95% CI of win ratio, 0.77-1.10; P = .11). CONCLUSIONS AND RELEVANCE: This randomized clinical trial failed to demonstrate efficacy for reldesemtiv in slowing functional decline in ALS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04944784.
引用
- Shefner JM, Cudkowicz ME, Genge A, et al. Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40126464. doi:10.1001/jamaneurol.2025.0241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。